Announced
Completed
Synopsis
Gilead Sciences, a research-based biopharmaceutical company, completed the acquisition of MYR, a German biotechnology company, from High-Tech Gruenderfonds Management and Maxwell Biotech Venture Fund for c. $1.8bn. “We are proud of our achievement in bringing Hepcludex from preclinical stage to patients in need within such a short timeframe. We are excited to join Gilead, whose experience in the hepatitis field and global infrastructure will realize the full potential of Hepcludex and provide access to as many patients as possible around the world with this debilitating disease,” Dmitry Popov, MYR Chief Executive Officer.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.